Kodiak Sciences Inc.
A clinical-stage biotech developing next-generation medicines for retinal diseases that cause blindness, aiming for longer-lasting anti-VEGF eye injections with candidates like Zenkuda (tarcocimab tedromer) and the bispecific KSI-501. Founded in 2009 as Oligasis and renamed Kodiak Sciences in 2015, the company takes its name from Alaska's mighty Kodiak bear — and fittingly, its Swiss manufacturing plant is called "Ursus," the Latin word for bear.
Granted 150.0K · Bought 5.41M
Granted 300.0K · Sold 1.34M
Granted 116.0K · Sold 74.6K
Granted 51.5K · Sold 41.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 86 transactions | — | 19.92M | 150.0K | 5.41M | — |
| Perlroth VictorChairman and CEO, Director · 5 transactions | -31.7% | 2.40M | 300.0K | — | 1.34M |
| Borgeson John A.Chief Financial Officer · 25 transactions | +28.6% | 216.0K | 116.0K | — | 74.6K |
| Ehrlich JasonSee Remarks · 31 transactions | +5.9% | 61.9Kas of Jun 2023 | 51.5K | — | 41.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +3.96M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.